Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy: Patients with seizures for six years or less

Sandra L. Helmers, David A. Griesemer, J. Christine Dean, Jorge D. Sanchez, Douglas Labar, Jerome V. Murphy, David Bettis, Yong D. Park, Robert M. Shuman, George L. Morris

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

BACKGROUND - This study retrospectively compared the effectiveness of vagus nerve stimulation (VNS) therapy among a constant cohort of patients in the patient outcome registry, which systematically monitors outcomes of patients receiving VNS therapy. Patients in the study had pharmacoresistant seizures for 6 years or less (early treatment group) or more than 6 years (late treatment group) before initiation of VNS therapy, and results are provided after both 3 and 12 months. REVIEW SUMMARY - Of 405 patients, 51 were in the early and 354 in the late treatment groups. Median age at onset of seizures was 7 years in the early and 4.5 years in the late treatment group. Seizure reduction of 100% was reported in 7.8% (early) and 3.7% (late) patients at 3 months and 11.8% (early) and 4.5% (late) at 12 months (P = 0.033). Reductions in seizure frequency greater than or equal to 90% for early and late treatment groups were similar: 11.8% (early) and 11.0% (late) at 3 months and 23.5% (early) and 17.0% (late) at 12 months. CONCLUSIONS - Patients treated earlier with VNS therapy were twice as likely to report no seizures as patients who had seizures for more than 6 years before they received VNS therapy. The effectiveness of VNS therapy should be assessed among other patients with pharmacoresistant seizures and lesser cumulative seizure loads.

Original languageEnglish (US)
Pages (from-to)160-164
Number of pages5
JournalNeurologist
Volume9
Issue number3
DOIs
StatePublished - May 1 2003

Fingerprint

Vagus Nerve Stimulation
Epilepsy
Seizures
Therapeutics
Age of Onset
Registries

Keywords

  • Database
  • Epilepsy
  • Registry
  • Seizures
  • Vagus nerve stimulation therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy : Patients with seizures for six years or less. / Helmers, Sandra L.; Griesemer, David A.; Dean, J. Christine; Sanchez, Jorge D.; Labar, Douglas; Murphy, Jerome V.; Bettis, David; Park, Yong D.; Shuman, Robert M.; Morris, George L.

In: Neurologist, Vol. 9, No. 3, 01.05.2003, p. 160-164.

Research output: Contribution to journalReview article

Helmers, SL, Griesemer, DA, Dean, JC, Sanchez, JD, Labar, D, Murphy, JV, Bettis, D, Park, YD, Shuman, RM & Morris, GL 2003, 'Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy: Patients with seizures for six years or less', Neurologist, vol. 9, no. 3, pp. 160-164. https://doi.org/10.1097/00127893-200305000-00004
Helmers, Sandra L. ; Griesemer, David A. ; Dean, J. Christine ; Sanchez, Jorge D. ; Labar, Douglas ; Murphy, Jerome V. ; Bettis, David ; Park, Yong D. ; Shuman, Robert M. ; Morris, George L. / Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy : Patients with seizures for six years or less. In: Neurologist. 2003 ; Vol. 9, No. 3. pp. 160-164.
@article{20af886e37ec426bafa554e33f94c540,
title = "Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy: Patients with seizures for six years or less",
abstract = "BACKGROUND - This study retrospectively compared the effectiveness of vagus nerve stimulation (VNS) therapy among a constant cohort of patients in the patient outcome registry, which systematically monitors outcomes of patients receiving VNS therapy. Patients in the study had pharmacoresistant seizures for 6 years or less (early treatment group) or more than 6 years (late treatment group) before initiation of VNS therapy, and results are provided after both 3 and 12 months. REVIEW SUMMARY - Of 405 patients, 51 were in the early and 354 in the late treatment groups. Median age at onset of seizures was 7 years in the early and 4.5 years in the late treatment group. Seizure reduction of 100{\%} was reported in 7.8{\%} (early) and 3.7{\%} (late) patients at 3 months and 11.8{\%} (early) and 4.5{\%} (late) at 12 months (P = 0.033). Reductions in seizure frequency greater than or equal to 90{\%} for early and late treatment groups were similar: 11.8{\%} (early) and 11.0{\%} (late) at 3 months and 23.5{\%} (early) and 17.0{\%} (late) at 12 months. CONCLUSIONS - Patients treated earlier with VNS therapy were twice as likely to report no seizures as patients who had seizures for more than 6 years before they received VNS therapy. The effectiveness of VNS therapy should be assessed among other patients with pharmacoresistant seizures and lesser cumulative seizure loads.",
keywords = "Database, Epilepsy, Registry, Seizures, Vagus nerve stimulation therapy",
author = "Helmers, {Sandra L.} and Griesemer, {David A.} and Dean, {J. Christine} and Sanchez, {Jorge D.} and Douglas Labar and Murphy, {Jerome V.} and David Bettis and Park, {Yong D.} and Shuman, {Robert M.} and Morris, {George L.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1097/00127893-200305000-00004",
language = "English (US)",
volume = "9",
pages = "160--164",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy

T2 - Patients with seizures for six years or less

AU - Helmers, Sandra L.

AU - Griesemer, David A.

AU - Dean, J. Christine

AU - Sanchez, Jorge D.

AU - Labar, Douglas

AU - Murphy, Jerome V.

AU - Bettis, David

AU - Park, Yong D.

AU - Shuman, Robert M.

AU - Morris, George L.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - BACKGROUND - This study retrospectively compared the effectiveness of vagus nerve stimulation (VNS) therapy among a constant cohort of patients in the patient outcome registry, which systematically monitors outcomes of patients receiving VNS therapy. Patients in the study had pharmacoresistant seizures for 6 years or less (early treatment group) or more than 6 years (late treatment group) before initiation of VNS therapy, and results are provided after both 3 and 12 months. REVIEW SUMMARY - Of 405 patients, 51 were in the early and 354 in the late treatment groups. Median age at onset of seizures was 7 years in the early and 4.5 years in the late treatment group. Seizure reduction of 100% was reported in 7.8% (early) and 3.7% (late) patients at 3 months and 11.8% (early) and 4.5% (late) at 12 months (P = 0.033). Reductions in seizure frequency greater than or equal to 90% for early and late treatment groups were similar: 11.8% (early) and 11.0% (late) at 3 months and 23.5% (early) and 17.0% (late) at 12 months. CONCLUSIONS - Patients treated earlier with VNS therapy were twice as likely to report no seizures as patients who had seizures for more than 6 years before they received VNS therapy. The effectiveness of VNS therapy should be assessed among other patients with pharmacoresistant seizures and lesser cumulative seizure loads.

AB - BACKGROUND - This study retrospectively compared the effectiveness of vagus nerve stimulation (VNS) therapy among a constant cohort of patients in the patient outcome registry, which systematically monitors outcomes of patients receiving VNS therapy. Patients in the study had pharmacoresistant seizures for 6 years or less (early treatment group) or more than 6 years (late treatment group) before initiation of VNS therapy, and results are provided after both 3 and 12 months. REVIEW SUMMARY - Of 405 patients, 51 were in the early and 354 in the late treatment groups. Median age at onset of seizures was 7 years in the early and 4.5 years in the late treatment group. Seizure reduction of 100% was reported in 7.8% (early) and 3.7% (late) patients at 3 months and 11.8% (early) and 4.5% (late) at 12 months (P = 0.033). Reductions in seizure frequency greater than or equal to 90% for early and late treatment groups were similar: 11.8% (early) and 11.0% (late) at 3 months and 23.5% (early) and 17.0% (late) at 12 months. CONCLUSIONS - Patients treated earlier with VNS therapy were twice as likely to report no seizures as patients who had seizures for more than 6 years before they received VNS therapy. The effectiveness of VNS therapy should be assessed among other patients with pharmacoresistant seizures and lesser cumulative seizure loads.

KW - Database

KW - Epilepsy

KW - Registry

KW - Seizures

KW - Vagus nerve stimulation therapy

UR - http://www.scopus.com/inward/record.url?scp=0038689164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038689164&partnerID=8YFLogxK

U2 - 10.1097/00127893-200305000-00004

DO - 10.1097/00127893-200305000-00004

M3 - Review article

C2 - 12808412

AN - SCOPUS:0038689164

VL - 9

SP - 160

EP - 164

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 3

ER -